Literature DB >> 25682607

The impact of category, cytopathology and cytogenetics on development and progression of clonal and malignant myeloid transformation in inherited bone marrow failure syndromes.

Michaela Cada1, Catherin I Segbefia1, Robert Klaassen2, Conrad V Fernandez3, Rochelle A Yanofsky4, John Wu5, Yves Pastore6, Mariana Silva7, Jeffrey H Lipton8, Josee Brossard9, Bruno Michon10, Sharon Abish11, MacGregor Steele12, Roona Sinha13, Mark Belletrutti14, Vicky Breakey15, Lawrence Jardine16, Lisa Goodyear17, Lillian Sung18, Mary Shago19, Joseph Beyene20, Preeti Sharma1, Bozana Zlateska1, Yigal Dror21.   

Abstract

Inherited bone marrow failure syndromes are a group of rare, heterogeneous genetic disorders with a risk of clonal and malignant myeloid transformation including clonal marrow cytogenetic abnormalities, myelodysplastic syndrome and acute myeloid leukemia. The clinical characteristics, risk classification, prognostic factors and outcome of clonal and malignant myeloid transformation associated with inherited bone marrow failure syndromes are largely unknown. The aims of this study were to determine the impact of category, cytopathology and cytogenetics, the three components of the "Category Cytology Cytogenetics" classification of pediatric myelodysplastic syndrome, on the outcome of clonal and malignant myeloid transformation associated with inherited bone marrow failure. We used data from the Canadian Inherited Marrow Failure Registry. Among 327 patients with inherited bone marrow failure syndrome enrolled in the registry, the estimated risk of clonal and malignant myeloid transformation by the age of 18 years was 37%. The risk of clonal and malignant myeloid transformation varied according to the type of inherited bone marrow failure syndrome but was highest in Fanconi anemia. The development of clonal and malignant myeloid transformation significantly affected overall survival. Mortality varied based on cytopathological group. The largest group of patients had refractory cytopenia. Clonal marrow cytogenetic abnormalities were identified in 87% of patients with clonal and malignant myeloid transformation, and different cytogenetic groups had different impacts on disease progression. We conclude that category, cytopathology and cytogenetics in cases of clonal and malignant myeloid transformation associated with inherited bone marrow failure syndromes have an important impact on outcome and that the classification of such cases should incorporate these factors. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Year:  2015        PMID: 25682607      PMCID: PMC4420212          DOI: 10.3324/haematol.2014.117457

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  41 in total

Review 1.  Classification of childhood aplastic anemia and myelodysplastic syndrome.

Authors:  Charlotte M Niemeyer; Irith Baumann
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

2.  Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study.

Authors:  Blanche P Alter; Neelam Giri; Sharon A Savage; June A Peters; Jennifer T Loud; Lisa Leathwood; Ann G Carr; Mark H Greene; Philip S Rosenberg
Journal:  Br J Haematol       Date:  2010-04-30       Impact factor: 6.998

3.  Myelodysplastic syndrome in childhood: a retrospective study of 189 patients in Japan.

Authors:  H Sasaki; A Manabe; S Kojima; M Tsuchida; Y Hayashi; K Ikuta; I Okamura; K Koike; A Ohara; E Ishii; Y Komada; S Hibi; T Nakahata
Journal:  Leukemia       Date:  2001-11       Impact factor: 11.528

Review 4.  Evaluating the prognosis of patients with myelodysplastic syndromes.

Authors:  C Aul; A Giagounidis; U Germing; A Ganser
Journal:  Ann Hematol       Date:  2002-09-24       Impact factor: 3.673

Review 5.  Cancer in dyskeratosis congenita.

Authors:  Blanche P Alter; Neelam Giri; Sharon A Savage; Philip S Rosenberg
Journal:  Blood       Date:  2009-03-12       Impact factor: 22.113

6.  Clonal evolution in marrows of patients with Shwachman-Diamond syndrome: a prospective 5-year follow-up study.

Authors:  Yigal Dror; Peter Durie; Hedy Ginzberg; Rebecca Herman; Anu Banerjee; Martin Champagne; Kevin Shannon; David Malkin; Melvin H Freedman
Journal:  Exp Hematol       Date:  2002-07       Impact factor: 3.084

7.  Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes.

Authors:  Ulrich Germing; Carlo Aul; Charlotte M Niemeyer; Rainer Haas; John M Bennett
Journal:  Ann Hematol       Date:  2008-06-25       Impact factor: 3.673

8.  Clonal chromosomal aberrations in bone marrow cells of Fanconi anemia patients: gains of the chromosomal segment 3q26q29 as an adverse risk factor.

Authors:  Holger Tönnies; Stefanie Huber; Jörn-Sven Kuhl; Antje Gerlach; Wolfram Ebell; Heidemarie Neitzel
Journal:  Blood       Date:  2003-01-02       Impact factor: 22.113

9.  Hematologic, clinical, and cytogenetic analysis in 109 patients with primary myelodysplastic syndrome. Prognostic significance of morphology and chromosome findings.

Authors:  V Parlier; G van Melle; P Beris; P M Schmidt; A Tobler; E Haller; M J Bellomo
Journal:  Cancer Genet Cytogenet       Date:  1994-12

10.  Syndrome of Shwachman and leukaemia.

Authors:  P C Huijgens; E A van der Veen; S Meijer; O G Muntinghe
Journal:  Scand J Haematol       Date:  1977-01
View more
  11 in total

1.  Comment on: "The impact of category, cytopathology and cytogenetics on development and progression of clonal and malignant myeloid transformation in inherited bone marrow failure syndromes".

Authors:  Blanche P Alter; Philip S Rosenberg
Journal:  Haematologica       Date:  2015-09       Impact factor: 9.941

2.  Response to comments from Drs. Alter and Rosenberg.

Authors:  Yigal Dror; Michaela Cada
Journal:  Haematologica       Date:  2015-09       Impact factor: 9.941

3.  Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults.

Authors:  Daria V Babushok; Monica Bessler; Timothy S Olson
Journal:  Leuk Lymphoma       Date:  2015-12-23

Review 4.  Mechanisms of leukemic transformation in congenital neutropenia.

Authors:  Daniel C Link
Journal:  Curr Opin Hematol       Date:  2019-01       Impact factor: 3.284

5.  Hematopoietic Stem Cell Transplantation for Shwachman-Diamond Syndrome.

Authors:  Kasiani Myers; Kyle Hebert; Joseph Antin; Farid Boulad; Lauri Burroughs; Inga Hofmann; Rammurti Kamble; Margaret L MacMillan; Mary Eapen
Journal:  Biol Blood Marrow Transplant       Date:  2020-05-16       Impact factor: 5.742

6.  Cellular and molecular architecture of hematopoietic stem cells and progenitors in genetic models of bone marrow failure.

Authors:  Stephanie Heidemann; Brian Bursic; Sasan Zandi; Hongbing Li; Sagi Abelson; Robert J Klaassen; Sharon Abish; Meera Rayar; Vicky R Breakey; Houtan Moshiri; Santhosh Dhanraj; Richard de Borja; Adam Shlien; John E Dick; Yigal Dror
Journal:  JCI Insight       Date:  2020-02-27

7.  Diagnosis and therapeutic decision-making for the neutropenic patient.

Authors:  James A Connelly; Kelly Walkovich
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 8.  Mechanisms of somatic transformation in inherited bone marrow failure syndromes.

Authors:  Haruna Batzorig Choijilsuren; Yeji Park; Moonjung Jung
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

9.  Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantation.

Authors:  Nicolas Waespe; Machiel Van Den Akker; Robert J Klaassen; Lani Lieberman; Meredith S Irwin; Salah S Ali; Mohamed Abdelhaleem; Bozana Zlateska; Mira Liebman; Michaela Cada; Tal Schechter; Yigal Dror
Journal:  Haematologica       Date:  2016-08-18       Impact factor: 9.941

10.  Association of isochromosome (7)(q10) in Shwachman-Diamond syndrome with the severity of cytopenia.

Authors:  Yuko Shimosato; Reo Tanoshima; Shin-Ichi Tsujimoto; Masanobu Takeuchi; Koji Sasaki; Ryosuke Kajiwara; Hiroaki Goto; Junichi Nagai; Masakatsu D Yanagimachi; Shuichi Ito; Shumpei Yokota
Journal:  Clin Case Rep       Date:  2017-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.